Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma.
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer. If left untreated, BCCs can become locally aggressive or even metastasize. Currently available treatments include local destruction, surgery, and radiation. Systemic options for advanced disease are limited. The Hedgehog (Hh) pathway is aberrantly activated in a majority of BCCs and in other cancers. Hh pathway inhibitors are targeted agents that inhibit the aberrant activation of the Hh pathway, with smoothened being a targeted component. Sonidegib is a novel smoothened inhibitor that was recently approved by the US Food and Drug Administration. This review focuses on BCC pathogenesis and the clinical efficacy of sonidegib for the treatment of advanced BCC.
Department of Dermatology, University of Texas, McGovern Medical School.
Hung Q
HQ
Doan
Department of Dermatology, University of Texas, McGovern Medical School.
Sirunya
S
Silapunt
Mohs Surgery Unit, Department of Dermatology; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael R
MR
Migden
Hedgehog pathway; clinical trials; nonmelanoma skin cancer
Nature. 2008 Sep 18;455(7211):406-10
18754008
Sci Transl Med. 2010 Sep 29;2(51):51ra70
20881279
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60
17494766
J Clin Oncol. 1990 Feb;8(2):342-6
2405109
Dermatol Clin. 2011 Apr;29(2):287-96, x
21421152
Teratology. 1968 Feb;1(1):5-10
5696817
Cell. 1996 Jun 14;85(6):841-51
8681379
Clin Cancer Res. 2011 Apr 15;17 (8):2502-11
21300762
Clin Cancer Res. 2016 Mar 15;22(6):1325-9
26546616
Hum Mol Genet. 1999 Feb;8(2):291-7
9931336
J Med Chem. 2008 Nov 13;51(21):6646-9
18842035
ACS Med Chem Lett. 2010 Mar 16;1(3):130-4
24900187
Development. 1998 Sep;125(18):3553-62
9716521
Int J Cancer. 1995 Feb 8;60(4):482-8
7829261
Clin Cancer Res. 2013 May 15;19(10):2766-74
23575478
JAMA Dermatol. 2016 Apr;152(4):452-6
26765315
Science. 1996 Jun 14;272(5268):1668-71
8658145
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14132-7
19666565
Clin Cancer Res. 2014 Apr 1;20(7):1900-9
24523439
Br J Dermatol. 2005 Jan;152(1):43-51
15656799
Nat Genet. 1996 Sep;14 (1):78-81
8782823
Nat Rev Cancer. 2008 Oct;8(10 ):743-54
18813320
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9
19246386
Science. 1998 Jun 5;280(5369):1603-7
9616123
Science. 2002 Aug 30;297(5586):1559-61
12202832
Bioorg Med Chem. 2008 Mar 15;16(6):2764-8
18249125
N Engl J Med. 2009 Sep 17;361(12 ):1164-72
19726763
Nat Chem Biol. 2009 Mar;5(3):154-6
19151731
Nature. 2003 Mar 20;422(6929):313-7
12629553
J Invest Dermatol. 1998 Jun;110(6):885-8
9620294
J Clin Oncol. 2014 Mar 10;32(8):745-51
24493717
Annu Rev Cell Dev Biol. 2011;27:513-37
21801010
Nature. 1998 Jan 1;391(6662):90-2
9422511
Acta Oncol. 1996;35(6):677-82
8938213
Eur J Cancer. 2009 Jan;45(2):228-47
19097774
Cancer Res. 2011 Jun 1;71(11):4002-14
21632555
J Clin Oncol. 2010 Dec 20;28(36):5321-6
21041712
Lipids. 1978 Oct;13(10):708-15
723484
J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5
27067394
J Am Vet Med Assoc. 1965 Oct 15;147(8):839-42
5894206
J Dermatol Surg Oncol. 1989 Mar;15(3):315-28
2646336
J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8
8176018
Nature. 2000 Aug 31;406(6799):1005-9
10984056
Oncogene. 2002 Apr 18;21(17 ):2670-8
11965540
Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402
15197337
Clin Cancer Res. 2011 May 15;17 (10 ):3378-87
21558397
Oncogene. 2009 Oct 8;28(40):3513-25
19633682
J Am Acad Dermatol. 2003 Mar;48(3):425-9
12637924
Arch Dermatol. 2010 Mar;146(3):283-7
20231499
Br J Dermatol. 2016 Jan;174(1):68-76
26409035
Steroids. 1969 May;13(5):579-88
4977212
Nat Rev Mol Cell Biol. 2013 Jul;14(7):416-29
23719536
Lancet Oncol. 2015 Jun;16(6):716-28
25981810